CAR33 expands in vivo and demonstrated divergent toxicity profiles in 2 RMs. (A) Representative schematic of CAR33 production and treatment of 2 RMs. (B) Values of total T cells and CAR33 T cells infused per kilogram bodyweight for both macaques and days after transplant (DPT) to CAR treatment. (C) Post-CAR cytokine response in both treated animals as measured by IL-6 and CRP. Colored X’s indicate treatment with toci (green), dexa (blue), and anakinra (orange). (D) Distribution of PB immune lineages before and immediately after CAR33 treatment. Population proportions determined by flow cytometry and matched to absolute cell counts determined by complete blood counts. Dex, dexamethasone; DPT, days post-transplant; NK cell, natural killer cell; toci, tocilizumab.